Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 5/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 2/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | REN | P00797 | 4/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | KLK7 | P49862 | 1/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7045270 | 1.00 | CACNA1B (0.43) | CACNA1BCYP3A4CYP2C9CYP2C19CTSL | |
| SCHEMBL7045269 | 0.91 | SLC15A1 (0.45) | CACNA1BCYP3A4CYP2C9CYP2C19CTSL | |
| SCHEMBL7045267 | 0.91 | SLC15A1 (0.45) | CACNA1BCYP3A4CYP2C9CYP2C19CTSL | |
| SCHEMBL5488362 | 0.87 | MMP1 (0.49) | CTSLCTSBCTSSCTSK | |
| SCHEMBL5488364 | 0.87 | MMP1 (0.49) | CTSLCTSBCTSSCTSK | |
| SCHEMBL3323188 | 0.84 | MMP2 (0.54) | CYP3A4CYP2C9CYP2C19CTSLCTSB | |
| SCHEMBL3323186 | 0.84 | MMP2 (0.54) | CYP3A4CYP2C9CYP2C19CTSLCTSB | |
| SCHEMBL1628776 | 0.83 | MMP2 (0.53) | CYP3A4CYP2C9CYP2C19CTSLCTSB | |
| SCHEMBL28638619 | 0.81 | SYK (0.45) | SYKUSP2 | |
| SCHEMBL7280308 | 0.81 | SLC15A1 (0.49) | CYP3A4CYP2C9CYP2C19ATMSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100125075-A1 | Antibacterial Agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2010-05-20 | — | — | US | disclosed |
| US-7186719-B2 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS (GB) | 2007-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125075-A1 | Antibacterial Agents | NQO2, DAO, Q6ZSR9 | CACNA1B 3984/4885CYP3A4 1204/4885CYP2C9 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.